Figure 4.

Schematic illustration showing the tumor suppressive role of macroH2A1.2 when is increased in breast cancer and prostate cancer in inhibiting osteoclastogenesis. MacroH2A1.2 will attenuate the expression of lysyl oxidase (LOX) and interact with EZH2 to raise the H3K27me3 levels to sustain gene silencing in order to inhibit tumor-induced osteoclastogenesis in breast cancer. In prostate cancer, macroH2A1.2 will directly interact with HP1α and H1.2 to suppress LTβ gene expressions, a key stimulator of osteoclastogenesis.